Schedule III Is Here. Hemp Got Nothing & Your Pet's CBD Is Caught in the Middle.
By Tim Clark | Published April 30, 2026
On April 22, 2026, Acting Attorney General Todd Blanche signed the DEA's final rule rescheduling cannabis from Schedule I to Schedule III. Headlines called it historic. The hemp industry called it irrelevant. Both are right.
Source: DEA Final Rule — Schedules of Controlled Substances: Rescheduling of FDA Approved Products Containing Marijuana From Schedule I to Schedule III (signed April 22, 2026) | 21 CFR Parts 1300, 1301, 1308, 1312
A Historic Rule With a Very Narrow Scope
The rescheduling is real. The scope is not what most people think. The DEA's final rule moves cannabis to Schedule III under a specific legal authority 21 U.S.C. 811(d)(1) that bypasses the normal HHS scientific evaluation process entirely. It's treaty-based, not science-based, grounded in U.S. obligations under the Single Convention on Narcotic Drugs.
What actually moves to Schedule III is narrow and precisely defined in the CFR amendments:
- FDA-approved drugs — currently, this means three drugs which use cannabis memetics or direct confirmers: Jazz Pharmaceuticals' Epidiolex (plant derived cannabidiol for seizure disorders), Camber Pharmaceuticals' Dronabinol (generic Marinol synthetic THC for nausea and vomiting caused by cancer chemotherapy), and Bausch Health US' Cesamet (synthetic nabilone for for nausea and vomiting caused by cancer chemotherapy
- Marijuana subject to a state medical marijuana license — dispensaries, cultivators, and processors operating under state-issued medical cannabis licenses in any of the 40 states with medical marijuana programs
- Marijuana extract and naturally derived Δ9-THC — only when contained in the above two categories
Everything else including every hemp-derived CBD product on the market stays exactly where it was.
Hemp Is Explicitly Excluded. Again.
The rule states it plainly in multiple places: naturally derived Δ9-THC does not include any material that falls within the definition of hemp under 7 U.S.C. 1639o. The 2018 Farm Bill drew a line between hemp and marijuana at 0.3% delta-9-THC on a dry weight basis. That line still stands. Schedule III did not move it, blur it, or acknowledge it needs clarification.
The legal reality: Cannabis sativa L. is simultaneously a Schedule III controlled substance (if it's marijuana in an FDA-approved drug or state medical program), a federally legal agricultural commodity (if it's hemp under the Farm Bill), and an unapproved food ingredient with no regulatory pathway (if it's CBD in a supplement or pet product). One plant. Three legal identities. Zero coherence.
For the hemp industry, and specifically for pet CBD brands, the Schedule III rule is not a win, a loss, or even a near miss. It is a non-event dressed in historic language.
The 2026 Hemp Cliff Nobody Is Talking About
While the industry celebrated Schedule III headlines, a quieter and more consequential deadline is approaching. Effective November 12, 2026, the hemp THC definition embedded in the 2018 Farm Bill's sunset provisions shifts from measuring only delta-9-THC to measuring total tetrahydrocannabinols including THCA.
This is not a minor technical adjustment. THCA converts to delta-9-THC when heated. A full-spectrum hemp product that tests at 0.28% delta-9-THC today could test well above 0.3% total THC when THCA is included in the calculation. Under the new definition, that product is no longer hemp. It is marijuana. It is Schedule I, or now Schedule III if it somehow qualifies, but it is no longer a legal agricultural commodity.
The 2024 Farm Bill reauthorization which would have addressed this stalled in Congress and has not been resolved. Multiple competing legislative proposals are in play, each with different THC thresholds, different cannabinoid definitions, and different agency authority structures. The DEA, FDA, and USDA are not aligned. Congress is not aligned. And November is not far.
For solventless hemp products: The total THC calculation is actually more favorable for solventless rosin than for solvent-extracted distillate, but still problematic at 0.4mg TTPC (Total THC Per Container). Solventless extraction preserves the native cannabinoid ratios in carboxylic acid form without over-concentrating specific fractions meaning THCA levels in compliant solventless products tend to remain lower and managably within range when put to the dilution rate of the finished retail ready product. This is one of several reasons solventless extraction is not just a purity argument but it's realistically a compliance argument. The crux of this argument depends on the FDA's interpretation and definition of a container be it as an intermediate or finished product.
The FDA Still Hasn't Answered the Basic Questions
Since the 2018 Farm Bill legalized hemp, the FDA has been the designated agency for determining how CBD can be legally sold as a food, a supplement, a cosmetic, or a drug. Eight years later in the wake of industry altering legislation the FDA has not published a permitted cannabinoid list of naturally derivable constituents. It has not defined what constitutes a 'container' in regards to in-process manufacturing or finished CBD products. It has not issued final guidance on CBD as a dietary supplement ingredient. It has not created a regulatory pathway for hemp-derived CBD in food for humans or animals. By now you may be asking, what have they actually been doing for 8 years???
This is not bureaucratic delay. It is a structural stalemate. The FDA's position that CBD cannot be a dietary supplement because it was first investigated as a drug (Epidiolex) has been challenged legislatively, litigated in federal court, and criticized by the agency's own advisory panels. Ironically, the position has not changed.
For pet CBD specifically, the situation is compounded by the fact that AAFCO, the body that governs animal feed ingredients, has also not established a definition or permitted use for hemp-derived CBD in pet food or supplements. State-by-state variation fills the void, creating a patchwork of enforcement that varies by jurisdiction, product type, and which agency happens to be paying attention.
Who Actually Wins From Schedule III
The beneficiaries of the Schedule III rule are specific and identifiable. They are not hemp brands. They are not pet wellness companies. They are not the millions of consumers buying CBD products at retail.
Multi-state operators (MSOs) holding state medical marijuana licenses gain the single most significant benefit via relief from Section 280E of the Internal Revenue Code. This provision of the tax code has prohibited Schedule I and II cannabis businesses from deducting ordinary business expenses like rent, payroll, marketing, etc. resulting in effective tax rates that can exceed 70%. Schedule III removes that burden for licensed medical marijuana operators. For large MSOs, this is worth tens of millions of dollars annually.
Pharmaceutical companies with FDA-approved cannabis-derived drugs gain a cleaner federal compliance framework and a more navigable path for future drug applications involving marijuana-derived compounds.
State-licensed dispensaries gain DEA registration pathways with expedited review, streamlined record-keeping that accepts state-required forms, and labeling flexibility that defers to state law.
Hemp brands, full-spectrum CBD companies, recreational dispensaries, and pet wellness brands operating entirely within the hemp framework gain nothing from this rule because as can plainly be deduced from the text, the rule was never written for them.
What This Means for Your Pet's CBD
If you are giving your dog or cat a hemp-derived CBD product (a tincture, a treat, a topical, etc.) the Schedule III rule changes nothing about the legal status of that product. It was derived from hemp. It is outside the marijuana definition. It is not covered by the rescheduling.
What matters for pet CBD in 2026 is not Schedule III. What matters is whether the Farm Bill gets reauthorized before November, whether the total THC definition change takes effect, and whether the FDA ever provides the regulatory clarity the industry has been waiting eight years to receive.
In the absence of that clarity, the most defensible position for any pet CBD brand is the same it has always been. Maunfacture and/or source utilizing only compliant hemp biomass, use extraction methods that don't concentrate or alter cannabinoid ratios unpredictably, test every batch at an ISO-accredited third-party laboratory, and make those results available to every customer for every product lot.
That is not a marketing position. It is the only rational response to a regulatory environment that has been structurally unresolved and fragmented for nearly a decade.
Frequently Asked Questions
No. The April 22, 2026 DEA final rule explicitly excludes hemp from Schedule III rescheduling. Hemp, defined as Cannabis sativa L. with no more than 0.3% delta-9-THC on a dry weight basis, remains outside the marijuana definition entirely. The rescheduling applies only to FDA-approved drug products containing marijuana and marijuana subject to state medical marijuana licenses.
Hemp-derived CBD products for pets occupy the same legal position they did before the Schedule III rule. However, the unresolved Farm Bill reauthorization and the November 2026 total THC definition change create real uncertainty for full-spectrum hemp products. Solventless hemp products with verified cannabinoid profiles are better positioned to remain compliant under the new definition than solvent-extracted distillate-based products.
Effective November 12, 2026, the legal definition of hemp shifts from measuring only delta-9-THC to measuring total tetrahydrocannabinols including THCA. This could reclassify many currently compliant full-spectrum hemp products as marijuana if their total THC content exceeds 0.3% when THCA is included in the calculation.
Multi-state operators (MSOs) with state medical marijuana licenses gain the most primarily through relief from IRS Section 280E tax restrictions that have imposed effective tax rates exceeding 70% on Schedule I/II cannabis businesses. Pharmaceutical companies and state-licensed dispensaries also benefit. Clinical researchers will also potentially benefit and finally will not have to rely solely on NIDA Sourcing for experimental materials and standards. Hemp brands and pet CBD companies are unaffected.
No. As of April 2026, the FDA has not published a permitted cannabinoid list, has not defined what constitutes a serving container for CBD products, and has not issued final guidance on CBD as a dietary supplement ingredient. This regulatory silence has persisted since the 2018 Farm Bill and continues to create compliance uncertainty for the entire hemp and pet CBD industry.
Schedule III applies to marijuana as defined in 21 U.S.C. 802(16) specifically in FDA-approved products or under state medical marijuana licenses. Hemp, defined separately under 7 U.S.C. 1639o, is explicitly excluded from the marijuana definition and therefore unaffected by the Schedule III rule. Both come from Cannabis sativa L. The legal distinction is entirely definitional not botanical.
